BIO International Convention
San Diego, USA
22 June 2026 - 25 June 2026
BIO International Convention
Northern Ireland at BIO International Convention
Northern Ireland is proud to be represented at this year's Bio International Convention by 11 leading organisations from across our life and health sciences sector – including innovative companies and world-class university research centres. Supported by Invest Northern Ireland, the delegation showcases the region’s strengths in cutting-edge research, advanced technologies, and global collaboration.
Meet the team and hear how Northern Ireland is helping shape the future of health.
Visit us on the UK Pavilion, stand 2221.
If you would like to schedule a meeting, please contact us.
To find out more about Northern Ireland's bio and pharma capabilities, visit our life and health sciences page.
Companies attending
Dia Beta Labs is a UK-based biotech company building on over 30 years of translational research from its founding research group at Ulster University, Northern Ireland. It is committed to transforming the lives of metabolic disease sufferers through the development of its novel therapeutic pipeline of disease-modifying peptides.
SignaCor is pioneering a first-in-class therapeutic approach for symptomatic hypertrophic cardiomyopathy - one that goes beyond symptom management to address the underlying pathology of the disease. SignaCor’s lead clinical stage candidate, Cardiaza, targets DNA methylation - a core mechanism behind fibrosis, hypertrophy, inflammation, and cardiac dysfunction.
AMPLY is a discovery partner that helps biotech teams move faster from new biology to partner-ready programmes. It harnesses TALON® (lncRNA target discovery) and AMPLYfolioAI® (novel molecule discovery + optimisation) to generate validated targets, differentiated peptide or ONT/ASO candidates, and data packages needed to support confident partnering and downstream development.
Re-Vana is a venture-backed ophthalmic drug delivery company advancing next-generation retinal therapies. Its proprietary EyeLief® and OcuLief® platforms are tunable, biodegradable, photo-crosslinked systems enabling sustained intravitreal release of biologics, peptides, and small or large molecules for 6–12 months without surgery, supporting internal programmes and selected strategic collaborations.
MMS Holdings (MMS) is an award‑winning, data‑focused clinical research organisation (CRO) supporting pharmaceutical and biotech companies through complex trial data and regulatory submission challenges. For 20 years, MMS has applied scientific rigor and data‑led judgment to help therapies reach patients faster and more responsibly.
Future Medicines Institute (FMI) is an industry-led research hub for Life and Health Sciences in Northern Ireland focusing on drug and device discovery, hosted by Queen’s University Belfast in partnership with Ulster University, Almac Group, Randox Laboratories, Fusion Antibodies, ProAxsis, Diaceutics, Sonrai Analytics and the Health Innovation Research Alliance NI.
VascVersa is developing the next wave of advanced therapies as treatments for vision loss. It aspires to create a future reality in which durable vision regeneration is affordable, equitably accessible, easy to administer and sustainably adopted by global economies. It is leading the therapeutic paradigm shift.
Ulster University has over 30 spin-out companies, with a valuation of around £22 million. Its investment arm, Innovation Ulster Limited (IUL), is a driving force for economic growth and innovation in Northern Ireland, translating university research into high-value ventures and generating over £51 million in turnover over the past decade.
Errigal Bio, an oncology-focused drug discovery company, has developed TiNA Discovery - a data driven, target discovery platform unlocking a new class of tumour specific antigen targets, termed 'Therapy Induced Novel Antigens'. 'TiNAs' have the potential to be applied across a range of immunotherapy modalities, for multiple solid tumour indications.
Axis Bio Services is a specialist preclinical CRO based in Northern Ireland, delivering in vivo and ex vivo research services across oncology, inflammation, and dermatology.
Working with biotech and pharmaceutical companies worldwide, it combines scientific rigour with a flexible, collaborative approach to help clients successfully advance their drug development programmes.
Fusion Antibodies is an early discovery partner located in Belfast, which designs and optimizes antibodies for the global healthcare market. Fusion’s expertise, process frameworks, and development platforms, enable its clients to develop diagnostics and therapeutics within the most challenging modalities and diseases. Fusion provides antibody services from discovery to supply.